Schmidt, C Max <br/><br/>
Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.  [electronic resource] 

 -  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract  Dec 2003 
 - 1024-33 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1091-255X 
<br/><br/><label>Standard No.: </label>10.1016/j.gassur.2003.09.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Apoptosis--drug effects<br/>Butadienes--pharmacology<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Cycle--drug effects<br/>Cell Division--drug effects<br/>Cell Line, Tumor<br/>Cyclooxygenase 1<br/>Cyclooxygenase 2<br/>Dinoprostone--metabolism<br/>Drug Synergism<br/>Enzyme Inhibitors--pharmacology<br/>Humans<br/>Isoenzymes--antagonists & inhibitors<br/>Liver Neoplasms--drug therapy<br/>Membrane Proteins<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Mitogen-Activated Protein Kinases--drug effects<br/>Nitriles--pharmacology<br/>Nitrobenzenes--pharmacology<br/>Pancreatic Neoplasms--drug therapy<br/>Prostaglandin-Endoperoxide Synthases--drug effects<br/>Signal Transduction--drug effects<br/>Sulfonamides--pharmacology